174 related articles for article (PubMed ID: 22745368)
1. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
Eissler N; Ruf P; Mysliwietz J; Lindhofer H; Mocikat R
Cancer Res; 2012 Aug; 72(16):3958-66. PubMed ID: 22745368
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
3. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
Thibault C; Nelson H; Chapoval AI
Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes.
Rossi GR; Mautino MR; Unfer RC; Seregina TM; Vahanian N; Link CJ
Cancer Res; 2005 Nov; 65(22):10555-61. PubMed ID: 16288048
[TBL] [Abstract][Full Text] [Related]
9. Depletion of activated Vbeta8+ T cells disrupts bispecific antibody directed antitumor immunity.
McConnell EJ; McLemore EC; Talac R; Joshi L; Nelson H
J Surg Res; 2004 Nov; 122(1):103-12. PubMed ID: 15522322
[TBL] [Abstract][Full Text] [Related]
10. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.
Ruf P; Lindhofer H
Blood; 2001 Oct; 98(8):2526-34. PubMed ID: 11588051
[TBL] [Abstract][Full Text] [Related]
11. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells incubated with irradiated tumor cells effectively stimulate T lymphocyte activation and induce enhanced expression of CD69, CD25 as well as production of IFNgamma and IL4.
Stegel V; Kopitar A; Jezersek Novaković B; Ihan A; Novaković S
Int Immunopharmacol; 2006 Jan; 6(1):79-89. PubMed ID: 16332516
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
14. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.
Zeidler R; Mysliwietz J; Csánady M; Walz A; Ziegler I; Schmitt B; Wollenberg B; Lindhofer H
Br J Cancer; 2000 Jul; 83(2):261-6. PubMed ID: 10901380
[TBL] [Abstract][Full Text] [Related]
15. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
16. Two new trifunctional antibodies for the therapy of human malignant melanoma.
Ruf P; Jäger M; Ellwart J; Wosch S; Kusterer E; Lindhofer H
Int J Cancer; 2004 Feb; 108(5):725-32. PubMed ID: 14696099
[TBL] [Abstract][Full Text] [Related]
17. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
18. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
19. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
20. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
Belani R; Weiner GJ
J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
